Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

“…(A-B) GCase levels as assessed by the CBE/4-MU method are significantly decreased in the het <i>GBA1</i> D409V KI mice at 5 months of age in both brain (A) and liver (B). …”

Modifying pregnenolone to decrease its lipophilicity results in decreased cellular uptake. by Jeffrey M. McManus (7512926)

Spontaneous oxycodone withdrawal initially flattens NREM power rhythms, decreases low frequency and increases high frequency power. by Michael Gulledge (20577135)

MVEC microvessel formation is restricted in hydrogels exhibiting increased stiffness or decreased concentration of adhesive peptides. by Rebecca A. Scott (488956)

“…An unpaired student’s t-test detect statistical significance, *p<0.05 for 7.5 wt% hydrogels containing 3 mM RGD relative to either (<b>A, C-F</b>) 15wt% hydrogels containing 3 mM RGD or (<b>G, I-L</b>) 7.5wt% hydrogels containing 1 mM RGD.…”

Fig 5 - by Xiaoqian Yang (797525)

Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

DXM administration increases time spent in the wake state and decreases that in NREM sleep. by Tomonobu Kato (17684578)